• Français (FR)
  • English (UK)
  • RIGHTS ISSUE
  • Home
  • Company
    • About us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
      • Partnerships
  • Nox Science
    • NOX Enzymes
      • NADPH Oxidase
      • NOX Enzyme Family
      • NOX Expression
    • NOX and Disease
      • Oxidative Stress and Disease
      • Physiological Functions of NOX
      • Fibrotic diseases
      • Neurodegenerative diseases
      • Cardiovascular diseases
    • Publications
  • Pipeline
    • Setanaxib
    • Preclinical NOX1 program
    • Research programs
  • Investors
    • Stock information
    • Analyst coverage
    • Contribution project
      • Press release
      • Project presentation
      • Documentation
      • Shareholders general meeting
    • Press releases
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Events and presentations
    • Regulated information
      • Financial information
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
      • Other regulated information
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
      • Governance
      • OCABSA warrants
    • Shareholder information
      • Shareholders’ meetings
        • 2020
        • 2019
          • AGM of June 13, 2019
          • AGE of January 2019
        • 2018
          • AGM of june 13, 2018
        • 2017
          • AGM of June 15, 2017
          • AGM of February 28, 2017
        • 2016
        • 2015
        • 2014
      • Agenda
  • News and Events
    • Press releases
    • Events and presentations
    • Media
      • Press clippings
      • Interviews
  • Contacts
  • RIGHTS ISSUE
  • Slide 1 GB
  • Slide 2
Previous Next Play Pause

News

See all news
PrevNext
2020-01-16 - 19:30
Genkyotex provides business update and reports gross cash position at ...
2020-01-13 - 17:00
Half-yearly report on Genkyotex’s liquidity contract with Kepler Che...
2019-12-03 - 07:00
Genkyotex reports progress of Setanaxib phase 2 investigator initiated...
2019-10-24 - 18:00
Genkyotex provides business update and reports cash position at Septem...
2019-09-19 - 18:00
Genkyotex Announces First Half 2019 Results
2019-08-20 - 17:30
Genkyotex Extends Conversion Period for Outstanding €1.6 Million Con...
2019-07-25 - 07:00
Genkyotex announces positive post-hoc analysis of PBC phase 2 trial an...
2019-07-22 - 07:00
The WHO recognizes NOX inhibitors as new therapeutic class and approve...

Events

See all events
PrevNext
2019-10-25 - 11:00
Investor Presentation October 2019
2019-07-25 - 13:30
Conference call July 25 2019 – Inhibiting NOX enzymes to treat ...
2019-07-24 - 19:00
Genkyotex conference call on July 25, 2019 at 2 pm CEST
2019-07-03 - 12:00
Genkyotex invitation to Biotech Agora in Paris on July 10, 2019
2019-05-02 - 13:00
Phase 2 trial of GKT831 in patients with primary biliary cholangitis ...
2019-04-24 - 14:00
ILC2019 Presentation – GKT831 Phase 2 in PBC
2018-11-05 - 15:00
Management presentation on positive interim Phase 2 results in PBC
  • Legal terms

Back to Top

© 2020 genkyotex.com